Publikationen von Martin L. Sos
Alle Typen
Zeitschriftenartikel (29)
1.
Zeitschriftenartikel
21 (5), S. 821 - 830 (2022)
CD74-NRG1 fusions are oncogenic in vivo and induce therapeutically tractable ERBB2:ERBB3 heterodimerization. Molecular Cancer Therapeutics 2.
Zeitschriftenartikel
9 (14), S. 4991 - 5007 (2020)
Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. Cancer Medicine 3.
Zeitschriftenartikel
19 (9), S. 2584 - 2591 (2013)
Characteristics of lung cancers harboring NRAS mutations. Clinical Cancer Research 4.
Zeitschriftenartikel
5 (209), 209ra153 (2013)
A genomics-based classification of human lung tumors. Science Translational Medicine 5.
Zeitschriftenartikel
18 (17), S. 4682 - 4690 (2012)
Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clinical Cancer Research 6.
Zeitschriftenartikel
31 (20), S. 3961 - 3975 (2012)
AATF/Che-1 acts as a phosphorylation-dependent molecular modulator to repress p53-driven apoptosis. EMBO Journal 7.
Zeitschriftenartikel
44 (10), S. 1104- - 11xx (2012)
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics 8.
Zeitschriftenartikel
109 (42), S. 17034 - 17039 (2012)
A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America 9.
Zeitschriftenartikel
31 (46), S. 4811 - 4814 (2012)
Genetic insight and therapeutic targets in squamous-cell lung cancer. Oncogene 10.
Zeitschriftenartikel
3 (90), S. 90ra59 - 90ra59 (2011)
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Science Translational Medicine 11.
Zeitschriftenartikel
1 (1), S. 78 - 89 (2011)
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discovery 12.
Zeitschriftenartikel
17 (23), S. 7394 - 7401 (2011)
ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clinical Cancer Research 13.
Zeitschriftenartikel
17 (11), S. 1504 - 1508 (2011)
A crucial requirement for Hedgehog signaling in small cell lung cancer. Nature Medicine 14.
Zeitschriftenartikel
19 (1), S. 429 - 439 (2011)
Synthesis and biological evaluation of 7-substituted-1-(3-bromophenylamino)isoquinoline-4-carbonitriles as inhibitors of myosin light chain kinase and epidermal growth factor receptor. Bioorganic and Medicinal Chemistry 15.
Zeitschriftenartikel
10, Art. 127 (2011)
L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer. Molecular Cancer 16.
Zeitschriftenartikel
53 (7), S. 2892 - 2901 (2010)
Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor. Journal of Medicinal Chemistry 17.
Zeitschriftenartikel
5 (1), S. e8919 - e8919 (2010)
Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling. PLoS ONE 18.
Zeitschriftenartikel
70 (3), S. 868 - 874 (2010)
Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Research 19.
Zeitschriftenartikel
2 (62), S. 62ra93 - 62ra93 (2010)
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Science Translational Medicine 20.
Zeitschriftenartikel
8 (22), S. 3652 - 3656 (2009)
Systematically linking drug susceptibility to cancer genome aberrations. Cell Cycle